Study aim: Evaluating the effect of the combination of BCc1 & Hep-S on the improvement of clinical & laboratory symptoms of hospitalized COVID-19 patients Design: Clinical trial involving a control group with parallel , double blind groups randomized according to block randomization form at phases 1&2 on 120 patients Settings and conduct: - Place: wards for hospitalized COVID-19 patients - Method: by blinding the patients and the clinician Participants/Inclusion and exclusion criteria: Inclusion criteria: hospitalized definite COVID-19 patients diagnosed via PCR & CT scan of the lungs, patients' filling out a consent form, patients won't be discharged within 48 hrs, patients' conditions won't be improving within 48 hrs Exclusion criteria: pregnancy, in lactation, patients with transplants, hereditary immunodeficiency, patients with a record of type 1 diabetes, addiction to alcohol or drugs Intervention groups: 1. Hospitalized COVID-19 patients: the patients would receive the standard COVID-19 regimen along with BCc1 nanomedicine in 3 servings per day according to the presented dosage. 2. Hospitalized COVID-19 patients: the patients would receive the standard COVID-19 regimen along with Hep-s in 3 servings per day according to the presented dosage. 3. Hospitalized COVID-19 patients: the patients would receive the standard COVID-19 regimen along with the combination of BCc1 & Hep-s in 3 servings per day according to the presented dosage. 4. Hospitalized COVID-19 patients: the patients would receive the standard COVID-19 regimen along with placebo in 3 servings per day according to the presented dosage. Main outcome variables: Hospitalization period, morality, CT scan images of the lungs,